Avience Biomedicals Ltd.
SMENSE₹196–208
₹ 22 Cr
1200 Shares
₹ 2,35,200
₹10
Financial Summary
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| 4,523.6 | 2,396.4 | |
| 73.15 | 40.86 | |
| 4,596.75 | 2,437.26 | |
| 3,378.8 | 1,986.01 | |
| 980.07 | 294.52 | |
| 723.18 | 214.11 |
Subscription Details
IPO Timeline
IPO Offer Start
18 Jun 2026
IPO Offer Ends
22 Jun 2026
25 Jun 2026
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | Part finances the capital expenditure towards setting up of a new | 140.453 |
| 2 | Funding the working capital requirement of our Company | 82.5 |
| 3 | General Corporate Purposes | 39.721 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
92.85%
Promoter stake
Post-IPO
64.59%
Promoter stake
Offered to Public
10,44,000
shares
Post Share Capital
35,42,885
shares
About the Company
Avience Biomedicals Limited is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) productsand medical devices in Noida, Uttar Pradesh, India. In vitro diagnostics (IVDs) are tests that can detect disease, conditions andinfections. In vitro simply means ‘in glass’, meaning these tests are typically conducted in test tubes and similar equipment, asopposed to in vivo tests, which are conducted in the body itself. In vitro tests can be done in laboratories, health care facilities oreven in the home. The tests themselves can be performed on a variety of instruments ranging from small, handheld tests to complexlaboratory instruments.Avience Biomedicals Limited commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM),Covid, Human Immunodeficiency Viruses (HIV), HBs AG, Malaria, Dengue and others aimed at aiding medical institutions withaffordable and good-quality solutions. Avience Biomedicals Limited has expanded its product range from IVD rapid test kits toinclude a comprehensive line of medical devices such as Serology products, Biochemistry Analyser and Biochemistry Reagents,showcasing a dedication to addressing various healthcare needs. Being purely into B2B and B2G market, our products cater toPathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing,the Company also act as distributors and traders of medical equipments
Use of Proceeds
1. Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh2. Funding the Working Capital Requirement of our Company3. To meet out the General Corporate Purposes
Avience Biomedicals Ltd. Latest News
IPO FAQs
The Avience Biomedicals Ltd. IPO has a total of ₹22 crore, calculated at the upper end of the .
The Avience Biomedicals Ltd. IPO is priced at ₹196–208 per share. bids must fall within this , against a of ₹10 per share.
The for the Avience Biomedicals Ltd. IPO is 1,200 shares, which is also the minimum order quantity — you have to apply for at least 1,200 shares, and in multiples of 1,200 beyond that.
The minimum investment in the Avience Biomedicals Ltd. IPO is about ₹2,35,200 — one lot of 1,200 shares, calculated at the lower end of the .
Bidding at the cut-off or upper price raises the amount blocked in your account.
The Avience Biomedicals Ltd. opens on 18 Jun 2026 and closes on 22 Jun 2026.
Applications have to be in before 5:00 PM IST on the closing day, and your UPI mandate needs to be approved by then as well.
Avience Biomedicals Ltd. shares were listed on 25 Jun 2026 on NSE.
Skyline Financial Services Pvt Ltd is the for the Avience Biomedicals Ltd. IPO.
The registrar processes the , refunds and the credit of shares to your demat account, so allotment-status queries go to them — phone 011-26847136/26833777.
Avience Biomedicals Ltd. IPO shares are listed on NSE.
Each Avience Biomedicals Ltd. share has a of ₹10.
Face value is the nominal value recorded in the company's books and is separate from the issue price you pay.
held 92.85% of Avience Biomedicals Ltd. before the IPO, which falls to 64.59% after the issue.
10,44,000 shares of Avience Biomedicals Ltd. are being offered to the public in this issue.
- 1.Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
- 2.Funding the Working Capital Requirement of our Company
- 3.To meet out the General Corporate Purposes
Fintellectual Corporate Advisors Pvt Ltd. is the book running lead manager for the Avience Biomedicals Ltd. IPO.
Pre-apply means placing your Avience Biomedicals Ltd. application before the subscription window actually opens. The bid is held and forwarded to the exchange on the opening day, so you don't have to submit it in the rush of the first morning.
Applying early doesn't improve your chances — when an issue is oversubscribed, the for investors is decided by a lottery, not by who applied first. Your money is only blocked once the application reaches the exchange.
You can apply in the Avience Biomedicals Ltd. IPO online using either UPI or ASBA as the payment method. ASBA applications are made through the net banking of a bank account that supports IPO applications — the bank blocks the amount in your account instead of debiting it. UPI applications are offered by brokers that don't provide banking services: you enter your UPI ID and then approve the mandate request in your UPI app.
Either route needs a demat account. You bid for at least one lot, at a price within the or at the cut-off price, and the money stays blocked in your bank account until the is finalised.
Your broker or bank confirms the bid once it has been submitted to the exchange, usually within a few minutes during the bidding window. A UPI application only goes live after you approve the mandate request — ignore it and the bid lapses, even though it looks placed.
You can check the Avience Biomedicals Ltd. bid independently on the NSE or BSE IPO bid-verification page a day after applying. An ASBA application also shows up as a blocked amount in your bank statement.